摘要
目的探讨酶联免疫吸附试验(ELISA)和间接免疫荧光法(IFA)检测严重急性呼吸综合征(SARS)冠状病毒(SARS-CoY)&体在SARS病原中诊断中的特异性及其在肿瘤患者血清中的假阳性问题。方法 应用ELISA和IFA检测了111例正常对照和40例肿瘤患者血清中SARS-CoV抗体的阳性率。结果在111例正常对照和40例肿瘤患者中,IgM抗体均阴性,IgG抗体在正常对照中的阳性率为3.6%(4/111),在肿瘤患者中的阳性率17.5％(7/40),IgC抗体诊断SARS的特异性为96.4％,两种抗体同时阳性诊断SARS的特异性为100％。经IFA检测,上述SARS-CoV抗体阳性者均为阴性。结论 IFA诊断SARS的特异性为100％,ELISA诊断SARS存在一定的假阳性。应用ELISA测定SARS-CoV抗体时,应同时测定两种抗体以降低诊断的假阳性率,提高诊断的特异性。
Objective To investigate the specificity of serological diagnostic testing for coronavirus antibody in patients with severe acute respiratory syndrome(SARS) and to discuss the fasle - positive of SARS - associated coronavirus(SAfiS - CoV) antibody in patients with cancer. Methods SARS - CoV IgG and IgM antibody was detected in serum specimens from 40 eancer patients with non - SARS and 111 healthy controls without SARS- CoV infection by enzyme - linked immunosorbent assays(ELISA) and indirect immunofluorescence antibody(IFA). Results Of 111 sera from healthy controls,4(3.6% ) were positive of SARS- CoV- IgG antibody and 111(100%) were all negative of SARS - CoV - IgM antibody; the specificity of SARS - CoV - IgG antibody for SARS patients was 96.4% , but the specificity of both SARS - CoV -IgG and IgM antibody for SARS patients was 100% . In 40 cases with cancer, positive rate of SARS - GoV - IgG antibody was 17.5% (7/40), and 40( 100%) were all negative of SARS - CoV - IgM antibody. Of all samples with positive SARS - CoV - IgG antibody for cancer patients using ELISA were ail negative by IFA.Conclusion This result suggested that the specificity of SARS- CoV antibodyOgG and IgM) for SARS patients was 100% by IFA, but there are low false - positive rates of SARS - CoV antibody in samples without SARS - CoV infection by ELJSA. The false - posotive with SARS - CoV - IgG antibody may be related to coated antigens with SARS - CoV and Vero - Fj6 cells.
出处
《医学检验与临床》
2003年第5期7-8,共2页
Medical Laboratory Science and Clinics
关键词
严重急性呼吸综合征
冠状病毒
抗体
肿瘤
假阳性
特异性
Severe acute respiratory syndrome Coronavirus Antibody Cancer False - posotive Specificity
